Galmed Pharmaceuticals Ltd. reported the execution of a definitive agreement for a $3 million equity investment in OnKai Inc. Concurrently, a strategic partnership agreement is being signed to advance both companies by leveraging their complementary knowledge and experience in their respective fields. Through this partnership, the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications, such as orphan drugs, and opportunities to participate in otherwise inaccessible clinical trials as a therapeutic option.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3916 USD | -0.23% | +5.04% | -13.93% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.93% | 2.35M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- GLMD Stock
- News Galmed Pharmaceuticals Ltd.
- Galmed Pharmaceuticals Forms a Strategic Partnership with OnKai